In the 1970s, the therapeutic effect of tamoxifen (Nolvadex), a breast cancer therapeutic agent, varied depending on the status of the estrogen receptor (ER) expression in patients with breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.